The Claim
Adding ezetimibe to statin therapy in patients at high cardiovascular risk reduces the incidence of non-fatal strokes by 6 events per 1,000 patients treated over six years, with low-certainty evidence indicating the true effect may differ from this estimate.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people at high risk for heart disease, adding ezetimibe to statin therapy results in 6 fewer non-fatal strokes per 1,000 patients over six years, though the reliability of this estimate is low.
See the scientific wording
Adding ezetimibe to statin therapy in patients at high cardiovascular risk may slightly reduce non-fatal strokes by 6 fewer events per 1,000 patients treated over six years, but the evidence for this effect is of low certainty, meaning the true effect could be smaller, larger, or nonexistent.
Lowering bad cholesterol in the blood reduces the buildup of fatty deposits in artery walls, which prevents blockages that can cut off blood flow to the brain and cause strokes.
What the research says
1 studyAdding ezetimibe to statins might prevent about 6 strokes per 1,000 high-risk people over six years, but scientists aren’t very sure because the data isn’t strong enough to be certain it’s real.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.